Novo Nordisk has officially launched its globally known diabetes and weight-management drug, Ozempic, in India. The once-weekly injectable treatment will be available starting at ₹8,800 for a four-week supply, the company announced on Friday.
Ozempic, which contains the active ingredient semaglutide, is approved in India for adults with uncontrolled type 2 diabetes, and is recommended alongside diet and exercise. The drug is available in 0.25 mg, 0.5 mg, and 1 mg doses, delivered through a pre-filled single-use pen designed for comfortable and painless subcutaneous injections.
The pricing for the three variants is as follows:
-
0.25 mg (starter dose): ₹8,800
-
0.5 mg: ₹10,170
-
1 mg: ₹11,175
Each pen contains four weekly doses.
Vikrant Shrotriya, Managing Director of Novo Nordisk India, said the launch marks an important step in expanding access to advanced diabetes care in the country.
“Bringing Ozempic to India is a major milestone. Supported by proven clinical results and strong global trust, Ozempic offers doctors an effective treatment option,” he said.
He added that the company aims to provide patients with a therapy that supports better blood-sugar control, meaningful weight management, and long-term heart and kidney protection through an easy-to-use weekly pen device.
“This launch underscores Novo Nordisk’s ongoing commitment to improving health outcomes for people living with chronic conditions,” he noted.
Ozempic was first approved by the U.S. FDA in 2017 as a treatment for type 2 diabetes. In the years since, it has gained widespread attention for its weight-loss benefits, driven by its ability to suppress appetite. Clinical studies have also shown that semaglutide reduces the risk of cardiovascular events and kidney complications in people with diabetes.
Novo Nordisk explained that Ozempic is a GLP-1 receptor agonist, a class of drugs that:
-
Improves glycaemic control and lowers HbA1c
-
Reduces appetite and food intake
-
Supports weight loss in people with type 2 diabetes
-
Lowers the risk of diabetes-related heart and kidney problems
With its arrival in India, Ozempic is expected to offer a new treatment pathway for millions living with type 2 diabetes and related health challenges.
